alexa Reverse Vaccinology: Developing Vaccine Against MDR Acinetobacter baumannii | Open Access Journals
ISSN: 2157-7560
Journal of Vaccines & Vaccination
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Reverse Vaccinology: Developing Vaccine Against MDR Acinetobacter baumannii

Ravinder Singh1, Neena Capalash2 and Prince Sharma1*

1Department of Microbiology, Panjab University, Chandigarh, India

2Department of Biotechnology, Panjab University, Chandigarh, India

*Corresponding Author:
Prince Sharma
Department of Microbiology, Panjab University
Chandigarh 160014, India
Tel: 91-9815957903
E-mail: [email protected]

Received date: May 09, 2016; Accepted date: May 20, 2016; Published date: May 24, 2016

Citation: Singh R, Capalash N, Sharma P (2016) Reverse Vaccinology: Developing Vaccine Against MDR Acinetobacter baumannii . J Vaccines Vaccin 7:319. doi: 10.4172/2157-7560.1000319

Copyright: © 2016 Singh R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Vaccines & Vaccination

Abstract

Emergence of resistance against drugs viz. carbapenems, fluoroquinolones, aminoglycosides is the major problem associated with Acinetobacter baumannii infections thus making it imperative to develop a suitable vaccine as an effective treatment option. Previous studies reveal that outer membrane proteins of A. baumannii could serve as vaccine candidates and provide partial or complete immunity against lethal doses in various mouse models. Recently, we have shown reverse vaccinology as a powerful tool to identify vaccine candidates. The immunoprotective efficacy of an outer membrane, putative pilus assembly protein, FilF, identified as a potential vaccine candidate was validated in A. baumannii associated murine pneumonia model and was found to provide 50% survival against A. baumannii lethal doses. NucAb, an outer membrane nuclease identified in silico as A. baumannii vaccine candidate, provided 20% survival on active and 40% survival on passive immunization.

Short Communication

Acinetobacter baumannii is a fast emerging nosocomial pathogen that has gained attention of medical fraternity worldwide [1,2]. It infects the patients in hospitals or immunocompromised individuals and makes the treatment difficult due to its multidrug resistance nature [3]. All commonly available antibiotics such as carbapenems, fluoroquinolones and aminoglycosides have failed to control this pathogen [4-7]. Colistin, considered as the last resort of antibiotic treatment, is now used against this pathogen but there are reports of emergence of colistin resistant A. baumannii strains [8-10]. Therefore, other than antibiotics, vaccine development appears as the promising and effective treatment option. People in intensive care units or in hospitals for longer durations can be vaccinated prophylactically before admission in order to protect them from this nosocomial pathogen, besides the therapeutic use of vaccine.

Currently, vast information about genomes and proteomes of A. baumannii strains is available and promising vaccine candidates can be identified using the computational tools [11-15]. These candidates can further be validated in laboratories using animal models. Highly immunogenic antigens showing little variation among different strains can be determined by conventional techniques but they are time consuming and can be applied only for cultivable microorganisms. Reverse Vaccinology allows a rapid and efficient analysis to find putative immunogenic antigens. This approach can be incorporated in initial study (Figure 1) and can provide such novel proteins which could not be found by conventional vaccinology [16-19]. From the available proteome of pathogen, one can predict putative antigens associated with surface as ideal vaccine candidates. Once shortlisted, these candidates can be cloned and overexpressed in E. coli and purified by affinity chromatography. Their immunogenicity can be validated in vivo in suitable animal models.

vaccines-vaccination-Experimental-design-prediction

Figure 1: Experimental design for the prediction and validation of immunoprotective efficacy of vaccine candidates from A. baumannii proteome.

This approach has successfully led to identification of antigens capable of eliciting protective immunity against N. meningitidis group B [15]. Similarly, conserved surface proteins conferring cross- protective immunity in several pathogens such as Porphyromonas gingivalis [12], Streptococcus pneumoniae [19], Chlamydia pneumoniae [20] and Streptococcus agalactiae [21] have been identified by reverse vaccinology and successfully used. In our earlier published work [22,23], we have analyzed the proteomes of A. baumannii strains and predicted 51 vaccine candidates and validated the immunoprotective potential of two of them (an outer membrane nuclease, NucAb, and FilF, a putative pilus assembly protein) in murine pneumonia model.

FilF is a putative pilus assembly protein that fulfilled in silico the criteria of an ideal vaccine candidate [22]. Its localization in outer membrane makes it interact with host immune system during infection. It has no trans-membrane helix that alleviates the problems encountered in cloning of this protein. And most importantly, its complete dissimilarity with the human and mouse proteome which does not leave any chance of autoimmune response generation by the host. Several other properties of this protein such as high adhesion probability, number of B cell and MHC class I & II binding epitopes and its ability to bind to MHC molecules strongly make it a promising vaccine candidate. The exact role of FilF in A. baumannii is unknown and no information is available how it was named as FilF. Conservation analysis by BLAST and Multalin shows its exclusive presence in genus Acinetobacter with little variation. Nuclease or NucAb, another vaccine candidate identified, was also found to be highly conserved in A. baumannii strains and several virulent Acinetobacter species [23].

To study the vaccine potential of candidates, there are a number of animal models developed. Mostly, mouse sepsis models are used to check the bacterial load in various organs and mice survival after lethal dose inoculation [24-27]. Pneumonia models by intranasal route have also been used in several studies [28-32] but this model does not aid in the survival parameter studies as intranasal route does not cause death of mice due to massive clearance of bacteria. Therefore, intranasal route has been used to cause pneumonia and bacterial load determination in lungs followed by intraperitoneal route to cause sepsis to determine the survival rate in mice [31]. In our studies [22, 23], we developed A. baumannii associated intratracheal murine pneumonia model by standardizing A. baumannii dose to cause lethal infection in BALB/c female mice. In our intranasal route attempts, it was found that mice clear a large proportion of bacterial dose and infection was not established in the lungs. Also, intranasal route with higher doses such as 108 and 109 cfu was unable to cause the death of mouse observed for a week. Our motive was to develop a pneumonia model which not only provides the bacterial load in lungs studies but also the survival of immunized mice. Therefore, we used intratracheal route to install live bacteria directly into the trachea leading to the infection (lobar pneumonia) establishment. A. baumannii dose was standardized and it was found that 108 cfu administered intratracheally caused the mice death within 24 to 48 hr. Hence, an A. baumannii associated murine pneumonia model was developed and immunoprotective efficacy of FilF was investigated in the lab. Several parameters such as antibody (IgG) titer and their neutralizing activity, bacterial burden in lungs, histopathological analysis, serum cytokine levels and survival rate were determined in this mouse model [22].

Decrease in bacterial load due to immunization is the indicator of vaccine efficacy. Bacteria spread to host organs and multiply leading to death. Immunization results in reduction in bacterial load and hence increased survival rate of host [22-24,26-28,31,32].

Cytokines perform various functions in host cell and are associated with the infection severity and inflammation. They are released by the infected cell to activate and recruit the immune cells against the pathogen. Levels of pro- as well as anti-inflammatory cytokines are determined to evaluate the efficacy of vaccines. Immunization with vaccine candidates decreases the levels of pro-inflammatory and increases the levels of anti-inflammatory cytokines [26,31]. Epithelial and endothelial cells release IL-33 on invasion by pathogen and on pro-inflammatory stimulation. IL-33 is an inducer of Th2 immune responses. It strongly promotes Th2 cytokine production and aids the pathogenesis of Th2 related diseases, particularly asthma [33]. IL-6 performs as pro- as well as anti-inflammatory cytokine and its levels are elevated in inflammatory states [34]. TNF-α and IFN-γ are released during infection and are associated with the systemic inflammation. IL-1β is another pro-inflammatory cytokine that is associated with the innate immunity and host responses on bacterial infection [35]. We have shown that FilF immunization significantly reduced the levels of pro-inflammatory serum cytokine such as TNF-α, IFN-γ, IL-1β, IL-33 and IL-6 whereas IL-10 (anti-inflammatory) levels remained comparable in unimmunized and immunized mice [22]. Previous reports have also demonstrated the effect of immunization on decrease in the levels of pro-inflammatory cytokines [24,31,32]. These reductions in cytokine levels are supported by the histopathology studies in which clear difference in infection severity between the organs of unimmunized and immunized mice can be seen [22,23,31,32].

In our studies [22,23], we found that immunization with outer membrane proteins elicited high antibody titer but was unable to provide 100% protection against lethal bacterial dose. There could be several possible reasons for this such as down regulation of certain membrane proteins by bacteria during the acquisition of antibiotic resistance and during the immunity development [36]. Several lines of evidence in our published study [22,23] supported the fact that FilF as sub-unit vaccine could limit the infection and provided protection (50% survival) from lethal bacterial dose challenge. On the other hand, active immunization with nuclease provided 20% survival which increased to 40% after passive immunization. The future of the A. baumannii vaccinology should be focused on a better and clear understanding of the natural infection process in both animal models and human beings. The route of infection and bacterial dose are critical in causing the infection. Appropriate mouse models and more promising vaccine candidates can be explored to develop the best way to protect individuals at high risk. Antigens predicted by reverse vaccinology may represent most appropriate vaccine candidates.

Disclosures

The authors have no conflicts of interest nor any financial interests to disclose.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 8300
  • [From(publication date):
    June-2016 - Sep 22, 2017]
  • Breakdown by view type
  • HTML page views : 8191
  • PDF downloads :109

Review summary

  1. Rubella Jane
    Posted on Jul 13 2016 at 6:18 pm
    The article contains summary of recent publications on vaccines against Acinetobacter baumannii. It may be a useful scientific literature helpful in the furtherance of research on vaccine development against Acinetobacter baumannii.
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords